Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2024年3月9日 - 12:03AM
Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported
the receipt of a formal notification from The Nasdaq Stock Market
LLC ("Nasdaq") that the Company has regained compliance with
Listing Rule 5450(a)(1), which requires the Company's American
Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00
per ADS. The Nasdaq staff made this determination of compliance
after the closing bid price of the Company's was at $1.00 per share
or greater for the prior 10 consecutive business days. Accordingly,
the Company has regained compliance with Nasdaq Listing Rule
5450(a)(1) and Nasdaq considers the prior bid price deficiency
matter now closed.
About Trinity Biotech
PlcTrinity Biotech develops, acquires, manufactures and
markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
Forward Looking StatementsThis
release includes statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “Reform Act”), including but not limited to
statements related to Trinity Biotech’s cash position, financial
resources and potential for future growth, market acceptance and
penetration of new or planned product offerings, and future
recurring revenues and results of operations. Trinity Biotech
claims the protection of the safe-harbor for forward-looking
statements contained in the Reform Act. These forward-looking
statements are often characterised by the terms “may,” “believes,”
“projects,” “expects,” “anticipates,” or words of similar import,
and do not reflect historical facts. Specific forward-looking
statements contained in this presentation may be affected by risks
and uncertainties, including, but not limited to, our ability to
capitalize on our purchase of the assets of Waveform, our continued
listing on the Nasdaq Stock Market, our ability to achieve
profitable operations in the future, the impact of the spread
of COVID-19 and its variants, potential excess inventory levels and
inventory imbalances at the company’s distributors, losses or
system failures with respect to Trinity Biotech’s facilities or
manufacturing operations, the effect of exchange rate fluctuations
on international operations, fluctuations in quarterly operating
results, dependence on suppliers, the market acceptance of Trinity
Biotech’s products and services, the continuing development of its
products, required government approvals, risks associated with
manufacturing and distributing its products on a commercial scale
free of defects, risks related to the introduction of new
instruments manufactured by third parties, risks associated with
competing in the human diagnostic market, risks related to the
protection of Trinity Biotech’s intellectual property or claims of
infringement of intellectual property asserted by third parties and
risks related to condition of the United States economy and other
risks detailed under “Risk Factors” in Trinity Biotech’s annual
report on Form 20-F for the fiscal year ended December 31, 2022 and
Trinity Biotech’s other periodic reports filed from time to time
with the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date the statements
were made. Trinity Biotech does not undertake and specifically
disclaims any obligation to update any forward-looking
statements.
Contact: |
Trinity Biotech plc |
Eric Ribner |
|
Des Fitzgerald |
LifeSci Advisors, LLC |
|
+353-1-2769800 |
+1-646 -751-4363 |
|
|
E-mail: investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
過去 株価チャート
から 8 2024 まで 9 2024
Trinity Biotech (NASDAQ:TRIB)
過去 株価チャート
から 9 2023 まで 9 2024